For Dendreon, it kind of all comes down to today.
An FDA panel is reviewing today whether to recommend approval of the Seattle company’s prostate cancer vaccine. Although the FDA is required to follow the recommendations of its expert panels, it generally does, so this is a big deal.
Big enough that trading of Dendreon shares has been suspended today to help avoid any wild swings if the decision is announced during Wall Street hours. In recent days, though, hopeful investors had pushed the stock price upward. Of course, about 25 precent of the shareholders also have sold the company’s stock short, betting that the vaccine won’t win approval. Here’s CNN’s story on that: http://money.cnn.com/2007/03/28/news/companies/dendreon/index.htm?source=yahoo_quote.
For a good look at the science behind the vaccine and an answer to why the FDA’s even looking at a drug that failed its main clinical trial goals, take a look at this article from Forbes, http://www.forbes.com/2007/03/28/prostate-cancer-treatment-biz-cx_mh_0328prostate.html?partner=yahootix.
As soon as I see word on the FDA panel’s decision, I’ll post it here.
Talk to us
- You can tell us about news and ask us about our journalism by emailing firstname.lastname@example.org or by calling 425-339-3428.
- If you have an opinion you wish to share for publication, send a letter to the editor to email@example.com or by regular mail to The Daily Herald, Letters, P.O. Box 930, Everett, WA 98206.
- More contact information is here.